Table 3.
Disease | Study | Cellular Origin of EV | EV Biomarkers | EV Pathological Significance | Reference |
---|---|---|---|---|---|
STEC-HUS | Ståhl, A.-L.; et al., Arvidsson, I.; et al. |
platelets, monocytes, neutrophils | Tissue factor, phosphatidylserine (PS), C3, C9 | Promotion of thrombosis EV reflect complement activation |
[22,78] |
STEC-HUS | Varrone, E.; et al., Ståhl, A.-L.; et al., Johansson, K.; et al. |
EV carrying Shiga toxin | Delivery system of Shiga toxin to the kidney involvement in renal cell injury |
[79,80,81] | |
TTP | Tahmasbi, L.; et al., Jimenez, J.J.; et al. |
platelets, endothelial cells |
CD62E (E-selectin), VWF, intercellular adhesion molecule 1 (ICAM-1), platelet endothelial cell adhesion molecule (PECAM-1; CD31) and endoglin (CD105) | Pro-coagulant and pro-adhesive roles | [82,83] |
TTP | Tati, R.; et al. | Endothelial cells | C3, C9 | EV reflect complement activation | [84] |